ITRM Overview

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is5.50 USD with a low forecast of 2.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Iterum Therapeutics PLC revenue for the last quarter amounts to 390.00K USD, decreased

Iterum Therapeutics PLC. EPS for the last quarter amounts to -0.20 USD, decreased -33.33

Iterum Therapeutics PLC (ITRM) has 9 emplpoyees as of March 11 2026.

Today ITRM has the market capitalization of 9.69M USD.